CHRM3 (Cholinergic Receptor Muscarinic 3) encodes the M3 muscarinic acetylcholine receptor, a Gq protein-coupled receptor expressed throughout the central and peripheral nervous systems. While M3 receptors are well-known for their roles in smooth muscle contraction, glandular secretion, and autonomic function, growing evidence demonstrates important functions in the central nervous system, including contributions to learning, memory, and synaptic plasticity.
The M3 receptor is distinguished from other muscarinic subtypes by its distribution pattern, pharmacological profile, and physiological functions. In the peripheral nervous system, M3 mediates parasympathetic responses including urinary bladder contraction, gastrointestinal motility, and salivary secretion. In the brain, M3 is expressed in regions involved in cognition and movement, though its functions are less well-characterized than M1 and M4 receptors.
This comprehensive review examines the structure, signaling mechanisms, expression patterns, and physiological functions of CHRM3, with particular emphasis on its roles in the central nervous system and potential relevance to neurodegenerative diseases.
¶ Gene and Protein Structure
The CHRM3 gene (Gene ID: 1129) is located on chromosome 1q41 and encodes a 532-amino acid protein. The gene structure includes:
- Promoter region: Contains response elements for various transcription factors
- Coding sequence: Single exon encoding the complete receptor protein
- Regulatory elements: Sites for activity-dependent and developmental regulation
The M3 muscarinic receptor follows the canonical seven-transmembrane GPCR fold:
Structural Features:
- N-terminal extracellular domain: Contains glycosylation sites important for folding and trafficking
- Transmembrane domain: Seven α-helices (TM1-TM7) forming the ligand-binding pocket
- Extracellular loops: Three loops participating in ligand recognition
- Intracellular loops: Three loops mediating G protein coupling and regulatory phosphorylation
- C-terminal tail: Contains serine/threonine residues for desensitization
¶ Ligand Binding
The M3 receptor binds acetylcholine and various pharmacological ligands:
- Orthosteric site: Deep within the transmembrane domain
- Key binding residues: Conserved aspartic acid in TM3 serves as primary agonist anchor
- Allosteric sites: Additional binding sites for modulatory compounds
M3 undergoes several modifications:
- N-linked glycosylation: At N-terminal asparagine residues
- Palmitoylation: At cysteine in C-terminal tail
- Phosphorylation: At serine/threonine residues for desensitization
CHRM3 predominantly couples to Gq/11 proteins, activating phospholipase Cβ (PLCβ):
-
Phospholipase Cβ Activation: Gq activates PLCβ, hydrolyzing PIP2:
- IP3 Production: Triggers calcium release from endoplasmic reticulum
- DAG Generation: Activates protein kinase C isoforms
-
Calcium Signaling: IP3-mediated calcium release activates:
- Calmodulin and calmodulin-dependent kinases
- Various calcium-dependent ion channels
- Transcription factors and gene expression
-
Protein Kinase C Activation: DAG and calcium co-activate PKC:
- Phosphorylation of ion channels
- Modulation of receptor function
- Regulation of cellular responses
The M3 receptor exhibits specific G protein coupling:
Gq/11 Family Members: CHRM3 primarily activates:
- Gαq (GNAQ) - most abundant in most tissues
- Gα14 (GNA14) - more restricted expression
- Gα15/Gα16 (GNA15) - hematopoietic cell expression
Coupling Efficiency: The efficiency of Gq coupling varies by:
- Cell type and receptor density
- Agonist efficacy and concentration
- Receptor phosphorylation state
- Availability of G protein subunits
Signaling Amplification: One activated M3 receptor can activate multiple G proteins, and each G protein activates one PLCβ enzyme, which produces many IP3 molecules, creating significant signal amplification.
The second messenger systems activated by M3 have characteristic dynamics:
Calcium Signaling: IP3-mediated calcium release is rapid but transient:
- Calcium release peaks within seconds
- Calcium is quickly cleared by pumps and exchangers
- oscillatory calcium signals can encode information
- Store-operated calcium entry replenishes ER calcium
PKC Activation: DAG and calcium together activate PKC:
- Multiple isoforms have different substrate specificities
- PKC can phosphorylate ion channels, receptors, and transcription factors
- Sustained PKC activation leads to desensitization
M3 activates additional cascades:
-
MAPK Pathways: ERK1/2 activation through multiple mechanisms
- Gq-PLCβ-PKC-ras-RAF-MEK-ERK
- β-arrestin-dependent ERK activation
- Transactivation of receptor tyrosine kinases
-
PI3K/Akt Pathway: Cell survival signaling
- Gβγ subunits can activate PI3K
- Akt promotes cell survival and metabolism
- Cross-talk with other growth factor pathways
-
cAMP Modulation: Cross-talk with cAMP pathways
- M3 can activate Gs in some cell types
- PKC can modulate adenylyl cyclase activity
- cAMP and Ca2+ pathways interact
Like other GPCRs, M3 signals through β-arrestin adapters:
- Receptor internalization via clathrin-coated pits
- ERK activation through β-arrestin scaffolds
- Akt signaling and cell survival
- β-arrestin-dependent bias can be therapeutically exploited
M3 signaling is terminated through multiple mechanisms:
Receptor Desensitization:
- GRK phosphorylation of the C-terminal tail
- β-arrestin binding blocks G protein coupling
- Receptor internalization removes it from the membrane
Second Messenger Metabolism:
- IP3 is quickly phosphorylated or degraded
- DAG is metabolized by lipases or kinases
- Calcium is sequestered back into stores
Receptor Recycling or Degradation:
- Internalized receptors can be recycled to the membrane
- Alternatively, receptors can be targeted for degradation
- Lysosomal and proteasomal pathways are involved
The outcome of M3 activation varies by cell type:
Neurons: In neurons, M3 activation typically causes:
- Increased neuronal excitability
- Enhanced neurotransmitter release
- Activation of transcription factors (CREB)
- Modulation of ion channel function
Smooth Muscle: In smooth muscle cells:
- Contraction through myosin light chain kinase
- Proliferation in some contexts
-Hypertrophy in disease states
Glandular Cells: In secretory cells:
- Enhanced secretion of enzymes, mucus, or other products
- Increased fluid transport
- Apical membrane trafficking
CHRM3 is highly expressed in peripheral organs:
- Urinary Bladder: Detrusor muscle M3 receptors mediate contraction
- Gastrointestinal Tract: Smooth muscle contraction and secretion
- Salivary Glands: Saliva production
- Lungs: Airway smooth muscle and mucus secretion
- Eyes: Pupillary constriction (via sphincter muscle)
M3 expression in the brain includes:
- Cortex: Moderate expression in various cortical regions
- Hippocampus: Expression in CA1-CA3 and dentate gyrus
- Striatum: Presence in medium spiny neurons
- Thalamus: Expression in various thalamic nuclei
- Hypothalamus: Regulation of autonomic functions
M3 is expressed in:
- Neurons: Both excitatory and inhibitory
- Glia: Astrocytes and microglia to limited extent
- Smooth muscle cells: Peripheral organs
- Epithelial cells: Glandular tissue
Urinary Bladder:
M3 receptors are the primary mediators of bladder contraction:
- Direct activation of detrusor smooth muscle
- Critical for voiding function
- Antagonists used to treat overactive bladder
Gastrointestinal Tract:
M3 mediates:
- Smooth muscle contraction
- Gastrointestinal motility
- Secretory responses
Other Peripheral Effects:
- Salivation
- Bronchoconstriction
- Pupillary constriction
- Gastrointestinal secretion
Learning and Memory:
M3 contributes to cognitive processes:
- Synaptic plasticity in hippocampus
- Object recognition memory
- Spatial learning
Motor Control:
M3 in basal ganglia circuits:
- Modulation of striatal neuron activity
- Potential relevance to movement disorders
Seizure Modulation:
M3 influences neuronal excitability:
- Status epilepticus involvement
- Anti-seizure drug targets
Neuroprotection:
M3 activation may provide:
- Pro-survival signaling
- Modulation of excitotoxicity
M3 antagonists are first-line treatments:
- Tolterodine, solifenacin, darifenacin
- Reduce bladder contractility
- Improve urinary frequency and urgency
M3 antagonists in respiratory therapy:
- Bronchodilation
- Reduced mucus secretion
M3 agonists can stimulate saliva:
- Pilocarpine, cevimeline
- Used for Sjögren's syndrome and radiation-induced dry mouth
M3 modulators for:
- Irritable bowel syndrome
- Constipation
- Gastroparesis
M3 has been investigated for AD treatment:
- Cognitive Enhancement: M3 agonists may improve memory
- Amyloid Processing: M3 can influence APP processing
- Cholinergic Replacement: Non-selective muscarinic approaches
M3 plays complex roles in seizure disorders:
- Pro-convulsant Effects: M3 activation can lower seizure threshold
- Anti-seizure Potential: Certain M3 ligands have anti-seizure effects
- Status Epilepticus: M3 involvement in prolonged seizures
M3 may contribute to:
- Motor and non-motor symptoms
- Potential for therapeutic targeting
M3 agonist clinical applications:
- Pilocarpine: FDA-approved for dry mouth (Salagen)
- Cevimeline: Dry mouth in Sjögren's syndrome
- Bethanechol: Urinary retention
Challenges:
- Lack of subtype selectivity
- Peripheral side effects
- Limited CNS penetration
M3 antagonist applications:
- Overactive bladder: Tolterodine, solifenacin
- COPD: Tiotropium (also M1/M4 activity)
- Gastrointestinal: Various antispasmodics
Selectivity Issues:
- M3 antagonists often affect other muscarinic subtypes
- Side effects related to non-selective action
Newer approaches aim for greater selectivity:
- M3-Selective Agonists: Reduced side effects
- M3-Selective Antagonists: Improved side effect profile
- Positive Allosteric Modulators: Enhanced endogenous signaling
¶ CNS Function and Neurodegeneration
M3 contributes to memory through:
-
Hippocampal Synaptic Plasticity:
- LTP induction and maintenance
- NMDA receptor modulation
- Calcium signaling cascades
-
Molecular Mechanisms:
- CREB activation and gene expression
- Protein kinase activation
- Synaptic protein regulation
-
Behavioral Evidence:
- M3 knockout mice show memory deficits
- M3 agonists enhance memory in models
Alzheimer's Disease:
M3 may be relevant to AD pathophysiology:
- Cholinergic deficiency affects M3 signaling
- Amyloid-β interactions with muscarinic receptors
- Potential for therapeutic modulation
Parkinson's Disease:
M3 in PD research:
- Striatal M3 expression and function
- Potential for motor symptom modulation
M3 interacts with:
- G Proteins: Gq/11 family (GNAQ, GNA14, GNA15)
- β-Arrestins: β-arrestin 1 and 2
- GRKs: G protein-coupled receptor kinases
- Scaffold Proteins: Various PDZ-containing proteins
M3 signaling intersects with:
- Dopamine Signaling: Basal ganglia interactions
- Glutamate Signaling: NMDA/AMPA receptor modulation
- GABA Signaling: Inhibitory modulation
- Other Cholinergic Receptors: Subtype interactions
| Compound |
Selectivity |
Clinical Use |
| Acetylcholine |
Non-selective |
Research |
| Muscarine |
Non-selective |
Research |
| Oxotremorine |
M1/M2/M3 |
Research |
| Pilocarpine |
M3 partial |
Dry mouth |
| Cevimeline |
M3 selective |
Dry mouth |
| Bethanechol |
M3 > M1/M2 |
Urinary retention |
| Compound |
Selectivity |
Clinical Use |
| Atropine |
Non-selective |
Various |
| Scopolamine |
M1/M3 > M2/M4 |
Motion sickness |
| Tolterodine |
M3 > M1/M2 |
Overactive bladder |
| Solifenacin |
M3 selective |
Overactive bladder |
| Darifenacin |
M3 selective |
Overactive bladder |
| Tiotropium |
M1/M3/M4 |
COPD |
- Structure-Based Design: Cryo-EM structures enable rational drug design
- Allosteric Modulation: Novel allosteric binding sites
- Signal Bias: G protein vs β-arrestin selectivity
- Subtype Selectivity: Improved M3-selective compounds
- Selectivity: Achieving true M3 selectivity remains difficult
- Peripheral vs CNS: Balancing central and peripheral effects
- Chronic Treatment: Long-term safety and efficacy
- Patient Stratification: Identifying responsive patients
- Combination Therapies: M3 modulators with other mechanisms
- Personalized Medicine: Biomarker-guided treatment
- Disease Modification: Beyond symptomatic treatment
| Feature |
M1 (CHRM1) |
M3 (CHRM3) |
| G Protein |
Gq |
Gq |
| Brain Expression |
High (cortex, hippocampus) |
Moderate |
| Primary CNS Role |
Memory, plasticity |
Modulatory |
| Peripheral Role |
Limited |
Smooth muscle, glands |
| Therapeutic Target |
AD |
OAB, dry mouth |
M3 occupies a unique position:
- Gq coupling (like M1, M5)
- Peripheral expression (like M2, M4)
- Intermediate CNS expression
- Dual CNS/peripheral function
Emerging research indicates CHRM3 plays a role in neuroinflammatory processes:
M3 receptors on microglia modulate:
- Cytokine production and release
- Phagocytic activity
- Antigen presentation
Astrocytic M3 receptors influence:
- Calcium wave propagation
- Glutamate uptake regulation
- Metabolic support functions
M3 modulation may affect:
- Neuroinflammatory responses in AD and PD
- Excitotoxicity through astrocyte modulation
- Disease progression through immune mechanisms
¶ M3 and Circadian Function
Recent studies reveal M3 exhibits circadian regulation:
CHRM3 expression shows:
- Circadian variation in hippocampus
- Time-of-day effects on M3-mediated responses
- Interaction with clock gene pathways
M3 contributes to:
- Arousal and wakefulness
- REM sleep modulation
- Autonomic regulation during sleep
Genetic variations in CHRM3 have been associated with:
- Bladder dysfunction susceptibility
- Cognitive performance variations
- Response to anticholinergic medications
CHRM1 expression is regulated by:
- Epigenetic modifications
- Neuronal activity
- Various transcription factors
M3 influences blood-brain barrier (BBB) properties:
M3 signaling affects:
- Tight junction integrity
- Transport mechanisms
- Endothelial cell activation
M3 modulates:
- Leukocyte trafficking
- Inflammatory responses at BBB
- CNS immune privilege
M3 contributes to metabolic regulation:
M3 activation influences:
- Hepatic glucose production
- Insulin secretion and sensitivity
- Energy expenditure
¶ Body Weight
M3 modulators may affect:
- Food intake regulation
- Energy balance
- Obesity risk
-
M3 Agonists:
- Cevimeline (approved for dry mouth)
- Pilocarpine (approved for dry mouth)
-
M3 Antagonists:
- Tolterodine, solifenacin, darifenacin (OAB)
- Tiotropium (COPD)
- M3-Selective Agonists: Improved CNS selectivity
- M3 PAMs: Allosteric enhancement
- Bitopic Ligands: Combined orthosteric/allosteric targeting
- Selectivity: True M3 selectivity over other subtypes
- CNS Penetration: Achieving adequate brain exposure
- Chronic Effects: Long-term safety profile
- Tissue Specificity: Targeting desired tissue/organ
CHRM3 knockout mice exhibit:
- Urinary bladder dysfunction
- Reduced gastrointestinal motility
- Altered cognitive function in some tests
- Salivary hypofunction
Transgenic expression studies reveal:
- M3 overexpression effects on smooth muscle
- Conditional knockout systems
- Disease model interactions
CHRM3 encodes the M3 muscarinic acetylcholine receptor, a Gq-coupled GPCR with diverse functions in both the central and peripheral nervous systems. While best characterized for its roles in peripheral organ function including urinary bladder contraction, gastrointestinal motility, and glandular secretion, M3 receptors are increasingly recognized for important functions in the brain. In the central nervous system, CHRM3 contributes to learning and memory processes, synaptic plasticity, and modulation of neuronal excitability. The receptor signals through Gq/11 proteins, activating phospholipase Cβ and generating IP3 and DAG, which lead to calcium release and protein kinase C activation. M3 has been implicated in Alzheimer's disease pathophysiology through cholinergic deficiency, amyloid-β interactions, and potential effects on amyloid processing. Additionally, M3 plays roles in neuroinflammation, circadian regulation, and blood-brain barrier function. Several M3-targeted drugs are in clinical use, including antagonists for overactive bladder (tolterodine, solifenacin, darifenacin) and agonists for dry mouth (pilocarpine, cevimeline). Ongoing research focuses on developing more selective M3 modulators, understanding M3's role in neurodegeneration, and exploring M3-targeted approaches for AD and other neurological disorders.